MTRI — Mentari Therapeutics Share News
0.000.00%
Last trade - 00:00- $802.28m
- $801.14m
Brief: Inmed Provides Update On Baymedica Rare Cannabinoid Business
Brief: InMed Reports Second Quarter Fiscal 2023 Financial Results
Brief: InMed Pharma Says Unable To File Financial Statements For Three Months Ended Dec 31, 2022 In Timely Manner
Brief: InMed Provides Business Update And Milestones For 2023
Brief: Inmed Says Jonathan Tegge Will Assume Role Of Interim Chief Financial Officer Effective December 12
Brief: InMed Pharmaceuticals Files Prospectus Relates To Offer, Resale By Selling Shareholders Of Up To 5.09 Mln Of Common Shares
Brief: InMed Pharmaceuticals Announces Closing Of $6 Mln Private Placement Priced At A Premium To Market
Brief: InMed Pharmaceuticals Announces $6 Million Private Placement Priced At A Premium To Market
Brief: InMed Provides Update On Management Changes
U.S. STOCKS ON THE MOVE-Natera, Grab, InMed
InMed starts studying effects of cannabinoids on nerve diseases; shares rise
Brief: Inmed Pharmaceuticals Advances Neurodegenerative Disease Program
Brief: Inmed Pharmaceuticals Reports First Quarter 2023 Loss Per Share $4.06
Brief: Inmed Pharmaceuticals Inc Files For Offer And Resale Of 2.1 Mln Common Shares By The Selling Shareholders
InMed Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: Inmed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results And Provides Business Update
InMed Pharmaceuticals Inc expected to post a loss of $5.50 a share - Earnings Preview
Brief: Inmed Pharmaceuticals Announces Closing Of $6 Mln Private Placement Priced At A Premium To Market
U.S. STOCKS ON THE MOVE-Dow Inc, Corteva, Marker Therapeutics